More After Hours:
TearLab $TEAR 13% LOWER; filed with the SEC to sell up to $15 million in units.
Ruby Tuesday $RT 11.2% HIGHER; reported Q4 EPS of $0.06, versus $0.10 reported last year. Revenue for the quarter came in at $254.9 million, versus $279.32 million reported last year. Same-restaurant sales (on a 13-week comparable basis) declined 1.6% compared to a 3.7% decrease in the fourth quarter of the prior fiscal year. Strategic review entering finale phase.
Nordson Corp $NDSN 10.9% LOWER; reported Q3 EPS of $1.78, $0.46 better than the analyst estimate of $1.32. Revenue for the quarter came in at $589 million versus the consensus estimate of $574.73 million. Nordson Corp. sees Q4 2017 EPS of $2.27-$2.46, versus the consensus of $1.49.
Fabrinet $FN 4.6% LOWER; reported Q4 EPS of $0.86, $0.03 better than the analyst estimate of $0.83. Revenue for the quarter came in at $370.5 million versus the consensus estimate of $362.57 million. GUIDANCE: Fabrinet sees Q1 2018 EPS of $0.78-$0.80, versus the consensus of $0.87. Fabrinet sees Q1 2018 revenue of $356-360 million, versus the consensus of $375.22
Tarena Int’l $TEDU 3.3% LOWER; reported Q2 EPS of $0.14*, $0.02 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $68.34* million versus the consensus estimate of $67.76 million. Tarena Int’l sees FY2017 revenue of $287.86-299.85 million, versus the consensus of $301.89 million.
Premier $PINC 2.4% LOWER; reported Q4 EPS of $0.50, $0.02 worse than the analyst estimate of $0.52. Revenue for the quarter came in at $403.1 million versus the consensus estimate of $400.4 million.
Zayo Group $ZAYO 2.2% LOWER; reported Q4 EPS of $. Revenue for the quarter came in at $638 million versus the consensus estimate of $639.05 million.
Pacira Pharmaceuticals $PCRX 1% HIGHER; Needham & Company initiates coverage with a Buy rating and a price target of $55.00.